This site is intended for U.S. Healthcare Professionals only.
Indication
SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.
Study Designs
Efficacy
Safety
MOA
Dosing
Resources
MENU
CLOSE
BMS Connect
Request a Rep
Visit Patient Site
Home
Demographics
Baseline characteristics
Co-Primary vs Placebo
PASI 75
PASI 90
Scalp
Long-Term Extension
Week 16 Safety Profile
Weeks 0-52
LTE Safety
SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
Otezla is a registered trademark of Amgen Inc.
© 2023 Bristol-Myers Squibb Company.
1787-US-2300483 07/23